CIBC World Keeps Sector Outperform on QLT

Analyst Matt Geller says FDA approval of a long-acting formulation of Eligard will substantially boost its sales

QLT Inc. (QLTI ) received FDA approval for a 6-month formulation of its Eligard compound. CIBC World reiterated its sector outperform rating on the shares.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.